At the recent Association of Women in Rheumatology annual conference, AWIR and ACR leaders discussed advocacy’s important role in supporting equitable rheumatologic care.
Lowest Price, Highest Risk? New Drug Policy’s Potential Effect on Rheumatology
On July 31, President Trump sent formal letters to the CEOs of 17 major pharmaceutical companies, laying out several requirements the companies must meet within 60 days or face unspecified consequences. These include Most-Favored-Nation pricing for Medicare, Medicaid and private markets.
Rheumatology Could Face New Challenges Under Drug Tariff Reforms
A 15% tariff on all European Union exports, including pharmaceuticals, went into effect on Aug. 7. The tariff could impact the cost of providing care, patient access to therapies and drug research and development.
DOJ Tightens Oversight of DEI Programs: Implications for Rheumatology
A July 30 memo from Attorney General Pam Bondi clarifies how federal anti-discrimination laws apply to programs that might involve discriminatory practices, including those that fall under the umbrella of diversity, equity and inclusion.
Countdown to ACR Convergence 2025: Early Registration Ends Aug. 21
Learn about the registration options and add-on opportunities associated with ACR Convergence 2025, to be held Oct. 24–29 in Chicago, Ill.
The What, Why & How of MIPS Exception Applications
Practices that have experienced extreme circumstances—including wildfires or flooding—can apply for exceptions for Quality Payment Program reporting. Applications for 2025 are open through Dec. 31.
The ACR Advocates for Reinstatement of Members of CDC’s Advisory Committee on Immunization Practices
With 20 partner organizations, the ACR submitted a letter to HHS Secretary Robert F. Kennedy, Jr., urging the reinstatement of the terminated experts and reaffirming its commitment to science-based immunization policy.
August Updates from the ACR Insurance Subcommittee
The Insurance Subcommittee of the Committee on Rheumatologic Care is working on behalf of ACR members to address critical coverage and reimbursement challenges.
New Diagnostic Code R76.81 Can Be Used to Identify Those at Risk of Developing RA
New ICD-10-CM code R76.81 can now be used for patients who have abnormal rheumatoid arthritis (RA)-related autoantibodies—but not RA—to improve early disease risk identification, preventive care and research.
2026 Medicare Physician Fee Schedule Proposed Rule Released
The proposed rule includes several proposals related to Medicare physician payment and the Quality Payment Program. Read more about the provisions the ACR will address during the comment period.
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 332
- Next Page »